Taken together, we present evidence that the EPHA2-signalling axis is activated in KRAS-altered CET-resistant CRC cell lines, as well as in a mCRC patient with KRASmt-associated acquired CET resistance. The gene discussed is EPHA2; the disease is colorectal carcinoma.